alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › available

available

2 studies tagged available, dated 2011-11-01 to 2020-03-20. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study 2020-03-20
  2. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor 2011-11-01

Studies

2 studies carry this tag.

Date range

2011 to 2020

Top journals

  • Alzheimer's & dementia (New York, N. Y.) 1
  • The Journal of neuroscience : the official journal of the Society for Neuroscience 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia (New York, N. Y.) 2020-03-20 Treatments

    The safety and PK results encourage further clinical development of PRI-002.

  2. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2011-11-01 Risk genes beyond APOE

    According to the amyloid cascade hypothesis, cerebral deposition of amyloid-β peptide (Aβ) is critical for Alzheimer's disease (AD) pathogenesis.

All topic tags with their study counts